TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells

[1] Bonner JA(2010)Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 21-28

[2] Harari PM(2010)Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape J Clin Oncol 28 4390-4399

[3] Giralt J(2011)Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition J Immunol 187 3383-3390

[4] Ferris RL(2011)Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity Immunol Res 50 248-254

[5] Jaffee EM(2009)Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells Cancer Immunol Immunother 58 1853-1864

[6] Ferrone S(2007)Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer Arch Otolaryngol Head Neck Surg 133 1277-1281

[7] Overdijk MB(2008)TLR7 and TLR8 as targets in cancer therapy Oncogene 27 190-199

[8] Verploegen S(2009)Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists J Immunotoxicol 6 257-265

[9] van den Brakel JH(2007)The frequency and suppressor function of CD4 + CD25highFoxp3 + T cells in the circulation of patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 6301-6311

[10] Lammerts van Bueren JJ(2007)First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer Clin Cancer Res 13 7119-7125

[1] Bonner JA(2010)Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 21-28

[2] Harari PM(2010)Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape J Clin Oncol 28 4390-4399

[3] Giralt J(2011)Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition J Immunol 187 3383-3390

[4] Ferris RL(2011)Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity Immunol Res 50 248-254

[5] Jaffee EM(2009)Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells Cancer Immunol Immunother 58 1853-1864

[6] Ferrone S(2007)Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer Arch Otolaryngol Head Neck Surg 133 1277-1281

[7] Overdijk MB(2008)TLR7 and TLR8 as targets in cancer therapy Oncogene 27 190-199

[8] Verploegen S(2009)Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists J Immunotoxicol 6 257-265

[9] van den Brakel JH(2007)The frequency and suppressor function of CD4 + CD25highFoxp3 + T cells in the circulation of patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 6301-6311

[10] Lammerts van Bueren JJ(2007)First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer Clin Cancer Res 13 7119-7125